Press releases

Warsaw, 9 June 2016


BIOTON S.A. and MSD, a part of the American concern Merck & Co., have concluded an agreement according to which BIOTON shall cooperate with MSD within the scope of development of the market of hypercholesterolemia treatment with an innovative medication - Ezetrol (ezetymib).

read more

Warsaw, 26 May 2016


On 25 May 2016 the Supervisory Board of Bioton S.A. ("Bioton", "Company") decided to form a strategy development committee whose principal task will be to raise Bioton's operations to global level and to develop diabetes products portfolio, as the main area of Company operation. Therefore, the Supervisory Board has decided to delegate its Chairman, Mr Jubo Liu and a Vice Chairman, Mr Dariusz Trzeciak, to directly supervise the process of development and implementation of the new strategy of the Company.

read more

Current reports

Warsaw, 6 September 2016

Consolidated "extended" semi-annual report for H1 2016

read more

Warsaw, 31 August 2016

Current report 2016/44 dated 30.08.2016, time 19.02 7:02 UTC

Conclusion of the agreement on disposal of MJ BIOTON Life Sciences Ltd shares

read more